Not Signed In -
Trastuzumab |
Herceptin |
Trastuzumab Systematic (IUPAC) name Humanized anti-HER2 antibody Identifiers CAS number 180288-69-1 ATC code ? PubChem ? DrugBank BTD00098 Chemical data Formula C6470H10012N1726O2013S42 Mol. weight 145531.5 g/mol Pharmacokinetic data Bioavailability ? Metabolism ? Half life 2-12 days Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Trastuzumab (Herceptin®) is an anti-cancer the ...
Wikipedia - [full article]
Trastuzumab Clinical Trials
- Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
ClinicalTrials.gov Identifier: NCT00301899 - Active, not recruiting
Breast Cancer
- TBP Study with Capecitabine Plus Minus Trastuzumab
ClinicalTrials.gov Identifier: NCT00148876 - Active, not recruiting
Breast Cancer
- Vinorelbine+Trastuzumab vs Docetaxel+Trastuzumab as 1. Line Treatment for HER2+ Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00430001 - Recruiting
Metastatic Breast Neoplasm
- GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
ClinicalTrials.gov Identifier: NCT00371488 - Recruiting
Breast Cancer
- Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
ClinicalTrials.gov Identifier: NCT00533936 - Recruiting
Breast Cancer
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of the HER2/neu Protein
ClinicalTrials.gov Identifier: NCT00004074 - Active, not recruiting
Cancer
- UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00146042 - Active, not recruiting
HER-2 Positive Metastatic Breast Cancer
- Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
ClinicalTrials.gov Identifier: NCT00005635 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Study Of SU011248 Or Placebo In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00243503 - Recruiting
Breast Neoplasms
- A Trial of LBH589 and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed on or After Trastuzumab
ClinicalTrials.gov Identifier: NCT00567879 - Not yet recruiting
Breast Cancer
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00004888 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00201760 - Recruiting
Breast Cancer
- Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00036868 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00004013 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00003612 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00107393 - Active, not recruiting
recurrent breast cancer; stage IV breast cancer
- Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00006825 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00006104 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Anastrozole With or Without Trastuzumab in Treating Postmenopausal Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00022672 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00054587 - Active, not recruiting
stage II breast cancer; stage IIIA breast cancer
- Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/neu-Expressing Cancer
ClinicalTrials.gov Identifier: NCT00084513 - Active, not recruiting
unspecified adult solid tumor, protocol specific
- Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
ClinicalTrials.gov Identifier: NCT00005831 - Active, not recruiting
Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
- GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/neu
ClinicalTrials.gov Identifier: NCT00085020 - Active, not recruiting
stage IV breast cancer; Male Breast Cancer; recurrent breast cancer
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00021255 - Active, not recruiting
stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
- Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/neu-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00077376 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
- Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00006123 - Active, not recruiting
stage IV breast cancer
- Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00054470 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
- A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00490646 - Not yet recruiting
Metastatic Breast Cancer
- Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00005970 - Active, not recruiting
stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
- Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
ClinicalTrials.gov Identifier: NCT00004067 - Active, not recruiting
stage II breast cancer; stage IIIA breast cancer
- Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00006108 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00024154 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
- Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
ClinicalTrials.gov Identifier: NCT00151034 - Active, not recruiting
Advanced Urothelial Cancer
- Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00041067 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab in Treating Women With Breast Cancer
ClinicalTrials.gov Identifier: NCT00045032 - Active, not recruiting
stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
- Paclitaxel With or Without Trastuzumab in Treating Patients With Inoperable, Recurrent, or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00003440 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; stage IIIB breast cancer
- Trastuzumab Plus Interleukin-2 in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00006228 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
- A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA)
ClinicalTrials.gov Identifier: NCT00567190 - Not yet recruiting
Metastatic Breast Cancer
- Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00009997 - Active, not recruiting
stage IIIB breast cancer; stage IIIA breast cancer; stage II breast cancer
- Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00004925 - Active, not recruiting
stage IIIB breast cancer; inflammatory breast cancer; stage IV breast cancer; recurrent breast cancer
- Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
ClinicalTrials.gov Identifier: NCT00047255 - Active, not recruiting
stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent breast cancer
- Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast
ClinicalTrials.gov Identifier: NCT00006109 - Active, not recruiting
stage IIIB breast cancer; stage IIIA breast cancer; inflammatory breast cancer; stage IV breast cancer; recurrent breast cancer
- Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
ClinicalTrials.gov Identifier: NCT00014430 - Active, not recruiting
stage IIIB breast cancer; stage IIIA breast cancer; stage IV breast cancer; recurrent breast cancer
- Trastuzumab and Irinotecan in Patients with Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00145821 - Recruiting
Advanced Breast Cancer
- Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ClinicalTrials.gov Identifier: NCT00006089 - Active, not recruiting
stage III endometrial cancer; stage IV endometrial cancer; recurrent endometrial cancer; endometrial adenocarcinoma
- Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00079326 - Recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab With or Without Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
ClinicalTrials.gov Identifier: NCT00004935 - Recruiting
stage IV breast cancer; recurrent breast cancer
- Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
ClinicalTrials.gov Identifier: NCT00042809 - Recruiting
unspecified adult solid tumor, protocol specific
- Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
ClinicalTrials.gov Identifier: NCT00126607 - Active, not recruiting
recurrent salivary gland cancer; high-grade salivary gland mucoepidermoid carcinoma; salivary gland acinic cell tumor; stage IV salivary gland cancer; ...
- Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
ClinicalTrials.gov Identifier: NCT00028535 - Active, not recruiting
recurrent breast cancer; recurrent gastric cancer; recurrent non-small cell lung cancer; recurrent ovarian epithelial cancer; ...
- Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/neu Overexpression
ClinicalTrials.gov Identifier: NCT00033514 - Recruiting
stage IV breast cancer; recurrent breast cancer
- Anastrozole With or Without Trastuzumab in Treating Postmenopausal Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00112450 - Recruiting
stage IV breast cancer; recurrent breast cancer
- ABI-007, Carboplatin, and Trastuzumab in Treating Patients With HER2/neu-Overexpressing Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00085605 - Recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab, Docetaxel, and Carboplatin in Treating Women with Stage II, Stage III, Or Inflammatory Breast Cancer
ClinicalTrials.gov Identifier: NCT00118053 - Active, not recruiting
inflammatory breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer
- Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2 Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00193063 - Active, not recruiting
Breast Cancer
- Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
ClinicalTrials.gov Identifier: NCT00193089 - Active, not recruiting
Breast Cancer
- Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00193076 - Active, not recruiting
Breast Cancer
- Trastuzumab Plus R115777 in Treating Patients with Advanced or Metastatic Cancer
ClinicalTrials.gov Identifier: NCT00005842 - Completed
Cancer
- Fulvestrant and/or Trastuzumab in Treating Postmenopausal Women With Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00138125 - Recruiting
stage IV breast cancer; recurrent breast cancer
- Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
ClinicalTrials.gov Identifier: NCT00004163 - Active, not recruiting
salivary gland malignant mixed cell type tumor; salivary gland poorly differentiated carcinoma; stage III salivary gland cancer; ...
- Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00535509 - Active, not recruiting
Breast Cancer
- Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00016367 - Active, not recruiting
stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer
- Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00093808 - Recruiting
recurrent breast cancer; stage IV breast cancer; Male Breast Cancer
- Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-Associated Cardiotoxicity
ClinicalTrials.gov Identifier: NCT00459771 - Recruiting
Breast Cancer
- Effects of G-CSF, Trastuzumab, and Vinorelbine on Immune Cell Function
ClinicalTrials.gov Identifier: NCT00169104 - Recruiting
Metastatic Breast Cancer
- Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab
ClinicalTrials.gov Identifier: NCT00532857 - Recruiting
Breast Cancer
- Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00086957 - Recruiting
stage IV breast cancer; Male Breast Cancer; recurrent breast cancer
- Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated with Trastuzumab.
ClinicalTrials.gov Identifier: NCT00130507 - Suspended
Breast Cancer
- ALTTO(Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation)Study; BIG 2-06 / N063D
ClinicalTrials.gov Identifier: NCT00490139 - Recruiting
Breast Cancer
- Bevacizumab and Trastuzumab (Herceptin®) in Treating Women With Relapsed or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00093535 - Recruiting
recurrent breast cancer; stage IIIC breast cancer; stage IV breast cancer; stage IIIB breast cancer
- Mannitol Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
ClinicalTrials.gov Identifier: NCT00397501 - Active, not recruiting
Brain and Central Nervous System Tumors; Breast Cancer; Cognitive/Functional Effects; Drug Toxicity; Psychosocial Effects/Treatment
- Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00088985 - Recruiting
recurrent breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer
- XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00386685 - Recruiting
Breast Neoplasms
- Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
ClinicalTrials.gov Identifier: NCT00403988 - Recruiting
Breast Neoplasms
- Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-Cyclophosphamide in Breast Cancer Patients
ClinicalTrials.gov Identifier: NCT00485979 - Recruiting
Breast Neoplasms
- Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00320385 - Active, not recruiting
Metastatic Breast Cancer
- Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00068341 - Recruiting
stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage II breast cancer
- Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
ClinicalTrials.gov Identifier: NCT00041470 - Active, not recruiting
Breast Cancer
- Phase II Trial of BIBW 2992 in Patients With HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
ClinicalTrials.gov Identifier: NCT00431067 - Recruiting
Breast Neoplasms
- Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00068757 - Recruiting
recurrent breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; Male Breast Cancer
- Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-Positive Breast Cancer (Study P05048)
ClinicalTrials.gov Identifier: NCT00550771 - Recruiting
Breast Neoplasm
- Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00399529 - Recruiting
Breast Neoplasms
- Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00053339 - Not yet recruiting
stage IV breast cancer; recurrent breast cancer
- Phase IV Capecitabine and Docetaxel Combination for Neoadjuvant Treatment of Patients with Recently Diagnosed Breast Cancer and with Trastuzumab for Patients That Are Positive for Her2-Neu.
ClinicalTrials.gov Identifier: NCT00127933 - Active, not recruiting
Breast Cancer
- Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00266110 - Recruiting
Breast Cancer
- Pilot Study of Docetaxel and Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00364611 - Recruiting
Breast Cancer
- Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00458237 - Recruiting
Breast Cancer
- Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
ClinicalTrials.gov Identifier: NCT00513292 - Recruiting
Breast Cancer
- PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
ClinicalTrials.gov Identifier: NCT00362973 - Recruiting
Breast Cancer
- Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00398489 - Recruiting
Breast Cancer
- Chemotherapy, G-CSF, and ABI-007 With or Without Trastuzumab in Treating Women With High-Risk Localized Breast Cancer
ClinicalTrials.gov Identifier: NCT00407888 - Recruiting
Breast Cancer
- Vinorelbine (Oral) Plus Trastuzumab for 1st-Line Treatment of HER2/Neu Overexpressing Breast Cancer
ClinicalTrials.gov Identifier: NCT00433095 - Recruiting
Metastatic Breast Cancer
- Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
ClinicalTrials.gov Identifier: NCT00482391 - Recruiting
Breast Cancer
- First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
ClinicalTrials.gov Identifier: NCT00520975 - Recruiting
Breast Cancer
- Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
ClinicalTrials.gov Identifier: NCT00238420 - Recruiting
Bladder Cancer
- Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00303992 - Recruiting
Breast Cancer
- Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00381901 - Recruiting
Breast Cancer
- Safety and Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
ClinicalTrials.gov Identifier: NCT00365365 - Recruiting
Breast Cancer
- A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
ClinicalTrials.gov Identifier: NCT00391092 - Recruiting
Breast Cancer
- Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
ClinicalTrials.gov Identifier: NCT00428922 - Recruiting
Breast Cancer
email this page
print this page
bookmark this page
feedback on this page
